2月6日，赛科希德涨5.1%，截至发稿，报34.59元/股，成交1.50亿元，换手率4.27%，总市值36.71亿 元。赛科希德股价已经连续3天上涨，区间累计涨幅15.55%。 资料显示，北京赛科希德科技股份有限公司位于北京市大兴区百利街19号院，成立日期2003年5月28 日，上市日期2020年8月6日，公司主营业务涉及主要从事血栓与止血体外诊断领域的检测仪器、试剂及 耗材的研发、生产和销售。主营业务收入构成为：试剂53.71%，仪器25.40%，耗材20.58%，其他(补 充)0.31%。 前海开源事件驱动混合A（000423）基金经理为王达。 截至发稿，王达累计任职时间2年335天，现任基金资产总规模7278.43万元，任职期间最佳基金回报 27.88%， 任职期间最差基金回报27.56%。 声明：市场有风险，投资需谨慎。 本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本 文出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑：小浪快报 从基金十大重仓股角度 数据显示，前海开源基金旗下1只基金重仓赛科希德 ...

Core Viewpoint - The company is acquiring 100% equity of two subsidiaries, Shijian Qihua and Huada Xifeng, for a total price of 365.7 million yuan, aiming to integrate cutting-edge technologies in spatial genomics and nanopore sequencing [1] Group 1: Acquisition Details - The acquisition involves cash payments of 158 million yuan for Shijian Qihua and 207.7 million yuan for Huada Xifeng, with additional investments of 70 million yuan and 60 million yuan respectively to support their business development [2] - The company will also provide a loan of 7 million yuan to Huada Xifeng at an interest rate of 2.5% for three years to assist with repayments and daily operations [2] Group 2: Financial Projections - Both Shijian Qihua and Huada Xifeng are currently unprofitable, but are expected to achieve profitability by 2026 and 2028 respectively, with cumulative profit targets of at least 5.01 million yuan and 8.28 million yuan [3] - If the profit commitments are not met, Huada Technology will provide cash compensation, and any impairment beyond the cumulative compensation will also be compensated [3] Group 3: Strategic Integration - The integration of Shijian Qihua and Huada Xifeng is expected to enhance the company's technological ecosystem, creating a complete technical matrix for sequencing products [3] - The companies share a strong alignment in upstream suppliers and downstream customer bases, which is anticipated to facilitate rapid integration and collaboration post-acquisition [4] Group 4: Revenue Forecast - The company forecasts revenues of 2.918 billion yuan, 3.383 billion yuan, and 3.972 billion yuan for 2025-2027, with year-on-year growth rates of -3.15%, 15.94%, and 17.43% respectively [4] - The projected net profit for the same period is -233 million yuan, -11 million yuan, and 102 million yuan, with significant year-on-year growth rates of 61.20%, 95.42%, and 1052.54% [4]

Core Viewpoint - The company, Berry Genomics, anticipates a net loss for 2025, projecting a net profit attributable to shareholders between -250 million to -170 million yuan, compared to -192 million yuan in 2024 [1][2] Financial Performance - The company expects a net loss of 165 million to 245 million yuan after deducting non-recurring items for 2025, with a corresponding loss of 192 million yuan in 2024 [1] - Revenue has declined during the reporting period, although operating cash flow remains stable [1] Asset Management - Berry Genomics has conducted a comprehensive review and impairment testing of its assets based on prudence, which has impacted the current net profit [1] - The company has increased its R&D investment, which has led to higher expenses affecting the current net profit [1] Business Focus - The main business of Berry Genomics includes gene testing services and related equipment, focusing on reproductive health, genetic disease testing, and technology services [1] - The company aims to integrate gene testing technology with artificial intelligence algorithms to drive innovation in precision medicine, which is expected to generate revenue [2] Market Position - The newborn gene screening business is progressing as expected, which is anticipated to positively impact the company's business layout in reproductive health [2] - From 2021 to 2024 and the first three quarters of 2025, the company's net profit, net profit attributable to shareholders, and net profit after deducting non-recurring items have consistently been negative [2] Shareholder Issues - Recently, the controlling shareholder, Gao Yang, faced a default in stock pledge repurchase business, resulting in the forced execution of 3.5352 million shares, accounting for 0.999% of the company's total share capital [2]

Core Viewpoint - Yangpu Medical (300030.SZ) expects to achieve a net profit attributable to shareholders of 12 million to 17.5 million yuan in 2025, marking a turnaround from losses, with a net profit excluding non-recurring gains and losses projected at 16.5 million to 24 million yuan, also indicating a return to profitability [1] Group 1: Financial Performance - The company anticipates a year-on-year decline in operating revenue of 15% to 20% during the reporting period [1] - Revenue from vacuum blood collection system products is primarily affected by a decrease in sales, leading to a downward trend in income [1] - Revenue from reagents, software products, and services is also expected to decline year-on-year [1]

Core Viewpoint - The company expects a significant improvement in net profit for 2025, projecting a range of 12 million to 17.5 million yuan, compared to a loss of 118 million yuan in the same period last year [1] Revenue Performance - The company's operating revenue is anticipated to decline by 15% to 20% year-on-year [1] - The vacuum blood collection system products are primarily affected by a decrease in sales, leading to a downward trend in revenue [1] - Revenue from reagents, software products, and services is also expected to see a year-on-year decline [1] Cost Management - The company has implemented systematic cost optimization measures and refined management practices, effectively reducing manufacturing costs [1] - Despite a downward trend in product prices, the company has successfully achieved a slight increase in gross margin year-on-year [1] - The total expenses and expense ratio have decreased year-on-year due to reasonable control of expenditures and continuous optimization of the expense structure [1]

1月22日，《人民日报》发文《狂购30多处房产，她是咋"借"到钱的》： "你们抓我做什么？买房的这些钱都是借的，借条上写得清清楚楚。"留置室里，重庆市某医院检验科原 主任佘倩（化名）故作镇定。 "这次对你采取留置措施，是掌握了线索的，别想蒙混过关！这套房子你只付了5万元，其他全是别人付 的，这怎么解释？"纪委监委工作人员正色道。 佘倩的业务能力广受认可，还获得不少荣誉，随着职务和影响力不断提升，她思想的"开关"开始松懈， 贪欲越来越大。 作为医院检验科主任，佘倩手握医疗设备采购权，不少医疗企业主动找上门来，送给她各种好处费。她 对房产情有独钟，为了设置"防火墙"，往往要求对方贷款为其购置房产，并代为持有，自己从不出面。 某医药公司实控人杨某为向该医院销售医疗设备和耗材，找佘倩"打招呼"，并送给她好处费182万余 元，其中大部分资金用于"借"给佘倩购房。 除了在医院的职务，佘倩还兼任重庆市临床检验中心副主任。她利用各种开会、检查之便，笑纳各 类"讲课费""评审费"——除了合规的金额之外，还另外收取一笔更大数额的现金。 "出差时，供应商为她提供了保姆式服务，吃饭、用车等全部有人安排得妥妥帖帖。"办案人员说，佘倩 ...

明德生物（002932）(002932.SZ)公告，公司与交易对手方签署《关于蓝怡(湖南)医疗器械有限公司之收 购协议》，拟于首期收购中以增资及股权收购方式先行取得蓝怡(湖南)医疗器械有限公司(简称"湖南蓝 怡")51%股权，首期收购后湖南蓝怡成为公司控股子公司，纳入公司合并报表范围。若湖南蓝怡于2026 年度至2028年度相关经营情况满足《收购协议》约定的相关前置条件，公司将根据协议约定进一步收购 湖南蓝怡剩余股权，前述两阶段收购完成后，公司将合计持有湖南蓝怡100%股权。本次增资及股权收 购湖南蓝怡51%股权的交易作价合计为3570.10万元。 湖南蓝怡成立于2020年9月，核心聚焦IVD仪器、试剂研发生产与服务，在糖化血红蛋白检测方面掌握 高效液相色谱法(HPLC)，以AH-600系列糖化血红蛋白分析系统为核心相关检测产品凭借精准高效、权 威认证、成本可控等优势，成为国产替代与慢病管理的核心产品。 公告称，公司与标的公司核心业务分别覆盖急危重症与慢病管理，形成天然互补，共同覆盖院前急救、 院中诊断、院后随访及居家管理全流程，通过本次交易，公司将实现产业链的横向拓展，有利于公司构 建完整的产品生态，提升对 ...

Group 1 - The company has reached an agreement with its debtor, Urumqi Rongxin Kanda Trading Co., Ltd., to settle outstanding accounts receivable amounting to RMB 609.94 million, which is part of a total receivable of RMB 692.05 million that has aged over five years [2][3] - The debtor is required to make the payment by January 20, 2026, and failure to do so will allow the company to claim the original debt amount along with a 20% penalty and all costs incurred in recovering the debt [2] - The recovery of this accounts receivable and the reversal of the corresponding bad debt provision is expected to positively impact the company's financial condition and operating results for the year 2026, with the exact impact to be confirmed by the annual audit [4] Group 2 - The company has fully settled the debt relationship with the debtor as of the announcement date, confirming that the payment of RMB 609.94 million has been received in full [3] - The reversal of the bad debt provision adheres to the relevant accounting standards and regulations, ensuring that it does not harm the interests of the company and its shareholders [4]

Core Viewpoint - Shuoshi Bio (688399) has successfully resolved a long-standing accounts receivable issue with Urumqi Rongxin Kangda Trading Co., Ltd, resulting in a positive impact on the company's financial status for 2026 [1] Group 1: Accounts Receivable Situation - The company reported an accounts receivable balance of 6.9205 million yuan from a business collaboration with Urumqi Rongxin Kangda Trading Co., Ltd as of December 31, 2025 [1] - The accounts receivable has aged over five years, and the company has made multiple attempts to collect the debt through communication, legal letters, and lawsuits, but the debtor failed to fulfill repayment obligations [1] - The company has fully provisioned for the bad debt in accordance with accounting standards, which has been reflected in the financial statements for the relevant periods [1] Group 2: Debt Settlement Agreement - The company has actively pursued debt collection and reached a settlement agreement with the debtor, stipulating that the debtor will pay 6.0994 million yuan by January 20, 2026, as full settlement of the 6.9205 million yuan accounts receivable [1] - As of the announcement date, the debtor has fully paid the agreed amount of 6.0994 million yuan, and the debt relationship has been completely settled [1] - The recovery of this accounts receivable and the reversal of the previously provisioned bad debt is expected to have a positive impact on the company's financial condition and operating results for the year 2026 [1]

Group 1 - Berry Genomics experienced a decline of 5.33% on January 16, with a stock price of 12.78 CNY per share, a trading volume of 288 million CNY, a turnover rate of 6.64%, and a total market capitalization of 4.518 billion CNY [1] - The company, established on April 14, 1997, and listed on April 22, 1997, is based in Beijing and specializes in high-throughput sequencing technology for genetic testing, along with the sale of equipment and reagents [1] - The revenue composition of Berry Genomics includes reagent sales at 45.74%, medical testing services at 31.24%, basic research services at 18.33%, equipment sales at 3.48%, and other sources at 1.20% [1] Group 2 - The top circulating shareholder data indicates that a fund under Yongying Fund ranks among the top shareholders of Berry Genomics, with the Medical Device ETF (159883) newly entering the top ten shareholders in the third quarter, holding 1.5268 million shares, which accounts for 0.46% of circulating shares [2] - The Medical Device ETF (159883) was established on April 22, 2021, with a current scale of 4.73 billion CNY, yielding 11.25% this year, ranking 708 out of 5531 in its category, and achieving a 17.13% return over the past year, ranking 3570 out of 4215 [2] - The fund has experienced a cumulative loss of approximately 45.72% since its inception [2]